Amarin Corp ADR
(NQ:
AMRN
)
0.6005
-0.0095 (-1.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amarin Corp ADR
< Previous
1
2
3
4
5
6
Next >
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
August 22, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
July 31, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
July 17, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
July 17, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
July 08, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Board of Directors Announces CEO Transition
June 04, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
May 28, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 06, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Reports First Quarter 2024 Business Update and Financial Results
May 01, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
April 24, 2024
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Announces Results of Annual General Meeting of Shareholders
April 22, 2024
- Shareholders Approve Share Repurchase Program of up to $50 Million -
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
April 15, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
April 08, 2024
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action
From
Amarin Corporation plc
Via
GlobeNewswire
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
April 06, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
April 03, 2024
Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039
From
Amarin Corporation plc
Via
GlobeNewswire
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
March 25, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
February 15, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Chairman & CEO Issue Letter to Shareholders
January 22, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
January 10, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 11, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
November 12, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Reports Third Quarter 2023 Financial Results
November 01, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
October 31, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
October 26, 2023
-- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting --
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
October 19, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Present at the 2023 Cantor Global Healthcare Conference
September 12, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
August 09, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
August 08, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
August 07, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.